Background Disease registries are a very useful tool to clarify and analyze in clinical practice differences between patients regarding epidemiology, prognostic, therapeutic efficacy, quality of life and socio-economic characteristics.
Objectives To evaluate the main differences at the beginning of the current biological therapy between the prevalent and incident patients included in REGISPONSERBIO.
Methods REGISPONSERBIO is a Spanish multicenter (17), prospective registry (3 year-follow-up, with clinical controls every six months) of patients with axial SpA (ASAS criteria) under biological treatment. All patients included should be under biologic treatment and have a minimum data set necessary to achieve the main objectives planed for the registry. The inclusion period extended between September 2013 and December 2014. The registry included two groups of patients: a) prevalent cases (patients receiving biological treatment prior to baseline visit) b) incident cases (patients who started biological therapy at the inclusion in the registry). In all patients the following data was collected at baseline: age, disease and treatment duration, gender, HLA B27, Body Mass Index (BMI), BASDAI, BASFI, CRP, ESR, metrological data, ASQoL, WAPAI, extra-articular manifestations, comorbidities, radiological study, biological treatment at the time of inclusion in the registry and concomitant treatments. For this study, characteristics between prevalent and incident cases were compared using t-Student and chi-square tests. Results are shown as mean (standard deviation) or relative frequencies.
Results This registry included 258 patients, 174 out of 258 (67%) were prevalent cases. The group of prevalent patients showed higher disease evolution: 15 (11) vs 8 (11) years (p<0.001), higher proportion of males: 144 (83%) vs 57 (69%) (p=0.01), less proportion of non radiographic axial spondylarthritis: 6 (3%) vs 12 (14%) (p=0.001) and higher proportion of HLA-B27 positive 145 (84%) vs 57 (69%) although this latter result did not reach statistical significance (p=0.06).
Conclusions The observed data suggest that the profile of patients starting biological therapy seems to be changing in the last years.
Disclosure of Interest None declared